An outline is given of the implications of stereoselectivity in biological action and the use of racemic fixed-ratio combinations in pharmacology and pharmacotherapeutics. Pitfalls of the neglect of stereochemistry, such as generation of senseless pharmacokinetic data, are exemplified and emphasized.
AriëNsEJ, SoudijnW, TimmermansPBMWM. Stereochemistry and biological activity of drugs.Oxford: Blackwell, 1982.
2.
SimonyiM. On chiral drug action. In: Medicinal research reviews. Vol. 4. New York: John Wiley & Sons, 1984: 359–413.
3.
AriëNsEJ. Stereochemistry, a basis for sophisticated non-nonsense in pharmacokinetics and clinical pharmacology.Eur J Clin Pharmacol1984; 26: 663–8.
4.
DrayerDE. Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview.Clin Pharmacol Ther1986; 40: 125–33.
5.
Series on chirality, trends in pharmacological sciences.TIPS1986; 7: 20–4; 60-5; 112-5; 155-8; 200-5; 227-30; 281-5.
6.
WilliamsK, LeeE. Importance of drug enantiomers in clinical pharmacology.Drugs1985; 30: 333–54.
7.
AriëNsEJ. Stereochemistry: a source of problems in medicinal chemistry.Med Res Rev1986; 6: 451–66.
8.
AriëNsEJ, MohrK. Stereochemische Irrwege in der Pharmakotherapie.Dtsch Med Wochenschr1985; 110: 1741–9.
9.
AriëNsEJ, Rensen JjsVAN, WellingW. Stereoselectivity in pesticide action: a notable source of problems.New York: Elsevier, in press.
10.
BeckettAH. Stereochemical factors in biological activity. In: Jucker E, ed.Prog Drug Res1959; 1: 456–524.
11.
AriëNsEJ. Steric structure and activity of catecholamines on α-and β-receptors. Vol. 7. In: Proceedings of the first international pharmacological meeting, Stockholm.Oxford: Pergamon Press, 1963: 247–64.
12.
PortoghesePS. Relationships between stereostructure and pharmacological activities. In: ElliotHW, CuttingWC, DreisbachRH, eds. Annual review of pharmacology. Vol. 10. Palo Alto, CA: Annual Reviews, 1970: 51–75.
13.
PatilPN, MillerDD, TrendelenburgU. Molecular geometry and adrenergic drug activity.Pharmacol Rev1975; 26: 323–92.
14.
Von KnabeJ. Untersuchungen zur Konfigurationsspezifität der Arzneimittelwirkung.Dtsch Apoth Ztg1984; 124: 685–91.
15.
OkhawaH. Stereoselectivity of organophosphorus insecticides. In: CoatsJr, ed. Insecticide mode of action.New York: Academic Press, 1982: 163–83.
16.
LehmannFPA, Rodrigues De MirandaJF, AriëNsEJ. Stereoselectivity and affinity in molecular pharmacology. In: Jucker E, ed.Prog Drug Res1987; 20: 101–42.
17.
LehmannFPA. Stereoselective molecular recognition in biology. In: CuatrecasasP, GreavesMF, eds. Receptors and recognition, vol. 5, series A. London: Chapman and Hall, 1978: 1–77.
18.
JennerP, TestaB. The influence of stereochemical factors on drug disposition.Drug Metab Rev1973; 2: 117–84.
19.
LowLK, CastagnolinJr. Enantioselectivity in drug metabolism. In: Annual reports in medicinal chemistry, vol. 13. New York: Academic Press, 1978: 304–15.
20.
HuttAJ, CaldwellJ. The metabolic chiral inversion of 2-aryl-propionic acids—a novel route with pharmacological consequences.J Pharm Pharmacol1983; 35: 693–704.
21.
JahnchenE, MullerWE. Stereoselectivity in protein binding and drug distribution. In: BreimerD, SpeiserP, eds. Topics in pharmaceutical sciences.New York: Elsevier, 1983: 109–17.
22.
DrayerDE. Protein binding of drugs, drug enantiomers, active drug metabolites and therapeutic drug monitoring. In: ReidenbergMM, ErillS, eds. Drug-protein binding.New York: Praeger, 1986: 332–47.
23.
KleemannA, EngelJ. Einführung. In: Pharmazeutische Wirkstoffe.Stuttgart: Georg Thieme Verlag, 1982.
SjöQuistF. Blood binding and drug monitoring. In: TillemanP, LindenlaubE, eds. Protein binding and drug transport. Symposia Medica Hoechst 20. Stuttgart: Schattauer Verlag, 1986: 429–43.
29.
Grech-BelangerO, TurgeonJ, GilbertM. Stereoselective disposition of mexiletine in man.Br J Clin Pharmacol1986; 21: 481–7.
